144 related articles for article (PubMed ID: 37975660)
1. Individual meropenem epithelial lining fluid and plasma PK/PD target attainment.
Rohani R; Yarnold PR; Scheetz MH; Neely MN; Kang M; Donnelly HK; Dedicatoria K; Nozick SH; Medernach RL; Hauser AR; Ozer EA; Diaz E; Misharin AV; Wunderink RG; Rhodes NJ
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0072723. PubMed ID: 37975660
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
[TBL] [Abstract][Full Text] [Related]
3. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
4. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.
Lodise TP; Sorgel F; Melnick D; Mason B; Kinzig M; Drusano GL
Antimicrob Agents Chemother; 2011 Apr; 55(4):1606-10. PubMed ID: 21300830
[TBL] [Abstract][Full Text] [Related]
5. Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia.
Rohani R; Scheetz MH; Donnelly HK; Donayre A; Kang M; Diaz E; Dedicatoria K; Hauser AR; Ozer EA; Nozick S; Qi C; Pawlowski AE; Neely MN; Misharin AV; Wunderink RG; Rhodes NJ;
J Antimicrob Chemother; 2022 Oct; 77(11):2956-2959. PubMed ID: 35869779
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.
Hanberg P; Öbrink-Hansen K; Thorsted A; Bue M; Tøttrup M; Friberg LE; Hardlei TF; Søballe K; Gjedsted J
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530848
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
[TBL] [Abstract][Full Text] [Related]
9. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
[TBL] [Abstract][Full Text] [Related]
10. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
[TBL] [Abstract][Full Text] [Related]
11. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
[TBL] [Abstract][Full Text] [Related]
12. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
[TBL] [Abstract][Full Text] [Related]
14. Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions.
Layios N; Visée C; Mistretta V; Denooz R; Maes N; Descy J; Frippiat F; Marchand S; Grégoire N
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205221. PubMed ID: 35099273
[TBL] [Abstract][Full Text] [Related]
15. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.
Benítez-Cano A; Luque S; Sorlí L; Carazo J; Ramos I; Campillo N; Curull V; Sánchez-Font A; Vilaplana C; Horcajada JP; Adalia R; Bermejo S; Samsó E; Hope W; Grau S
Crit Care; 2020 Feb; 24(1):55. PubMed ID: 32066497
[TBL] [Abstract][Full Text] [Related]
16. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
Louie A; Liu W; Fikes S; Brown D; Drusano GL
Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis.
Ohata Y; Tomita Y; Sunakawa K; Drusano GL; Tanigawara Y
Int J Antimicrob Agents; 2019 Sep; 54(3):292-300. PubMed ID: 31279154
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Bader JC; Lakota EA; Dale GE; Sader HS; Rex JH; Ambrose PG; Bhavnani SM
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
